EDISON, N.J., Dec. 29, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), announced today that John Sullivan-Bolyai will step down as Chief Medical Officer and take on a new role in the company, effective December 29, 2017.
Dr. Sullivan-Bolyai will serve as a part-time consultant to the company, where he will remain involved in key strategic decisions, as well as medical and clinical affairs.
“We thank John for all the hard work and dedication as Chief Medical Officer of ContraVir for the past three years,” said James Sapirstein, Chief Executive Officer of ContraVir. We wish him the best in the next phase of his career, and we look forward to his continued contributions to the success of our company.”
About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The Company is developing two novel anti-HBV compounds with complementary mechanisms of action. TXL™, designed to deliver high intrahepatic concentrations of TFV while minimizing off-target effects caused by high levels of circulating TFV, recently completed a Phase 2a trial. CRV431, the other anti-HBV compound, is a next-generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. In vitro and in vivo studies have thus far demonstrated that CRV431 reduces HBV DNA and other viral proteins, including surface antigen (HBsAg). For more information visit www.contravir.com.
